Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Abbvie signs up China’s I-Mab instead of Trillium, but several other early-stage contenders are looking at the novel immuno-oncology mechanism.
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
A $4.9bn buyout of Forty Seven means that Gilead remains focused on oncology, though cell therapy bulls are none the wiser.
Tackling the CD47 pathway has seen off several industry players, but Forty Seven continues proudly flying the flag.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Celgene’s surprise termination of a clinical trial makes for a day of soul-searching among other followers of the anti-CD47 approach.